Author details
Author Pierre Van Damme |
Available item(s) by this author (29)



An economic evaluation of varicella vaccination in Italian adolescents / Nancy Thiry in Vaccine, 22(2004)27-28 ([09/09/2004])
![]()
[article] An economic evaluation of varicella vaccination in Italian adolescents [printed text] / Nancy Thiry, Author ; Philippe Beutels, Author ; Francesco Tancredi, Author ; A. Zanetti, Author ; Paolo Bonanni, Author ; Giovanni Gabutti, Author ; Pierre Van Damme, Author . - 2004 . - 3546-3562.
Languages : English (eng)
in Vaccine > 22(2004)27-28 [09/09/2004] . - 3546-3562
Descriptors: Classification
W 1 Serials. Periodicals
Indexation
Adolescent ; Adult ; Age Factors ; Aged ; Chickenpox Vaccine ; Child ; Child, Preschool ; Cost of Illness ; Cost-Benefit Analysis ; Economics ; Encephalitis, Varicella Zoster ; Epidemiology ; Female ; Hospitalization ; Humans ; Italy ; Journal Article ; Male ; Markov Chains ; Mass Immunization ; Middle Aged ; Netherlands ; Peer Review ; prevention and control ; statistics and numerical data [Subheading]Abstract: An economic evaluation was performed to assess five varicella vaccination scenarios targeted to 11-year-old Italian adolescents. The scenarios were: "compulsory vaccination" of all adolescents, recommended vaccination of susceptible adolescents on the basis of an "anamnestic screening", a "blood test" or a combination of both ("both tests") and vaccination of adolescents in the private sector, at the parents' charge ("private vaccination"). Probabilities and unit costs were taken from published sources and experts opinion. The accuracy of the anamnestic screening (81.6% sensitivity and 87.3% specificity) was derived from a separate descriptive study among 344 Italian adolescents. The costs and benefits of each scenario were simulated using a Markov model and cost-effectiveness, budget-impact and cost-benefit analyses were conducted. Of all considered scenarios, "both tests" and "anamnestic screening" were the most appealing options with an estimated net direct cost of 5058 and 8929 per life-year gained (compared to no vaccination) versus 14,693-42,842 for the other scenarios. These two scenarios further resulted in substantial net savings for society (over 600,000 per cohort, BCR: 2.17). The need for a serological confirmation was highly dependent on the sensitivity of the anamnestic screening, which is believed to increase once such a program is launched. For practical considerations, "anamnestic screening" seems to be the most convenient option. Link for e-copy: http://tiny.cc/xktyn Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1773 [article]
[article] Convincing or confusing? : Economic evaluations of childhood pneumococcal conjugate vaccination [printed text] / Philippe Beutels, Author ; Nancy Thiry, Author ; Pierre Van Damme, Author . - 2007 . - 1355-1367.
Research Support, Non-U.S. Gov't
Review
Languages : English (eng)
in Vaccine > 25(2007)8 [02/09/2007] . - 1355-1367
Descriptors: Classification
W 1 Serials. Periodicals
Indexation
Child, Preschool ; Economics ; Humans ; immunology ; Infant ; Journal Article ; Netherlands ; Peer Review ; Pneumococcal Infections ; Pneumococcal Vaccines ; prevention and control ; Vaccines ConjugateAbstract: We review 15 economic analyses of pneumococcal conjugate vaccines, published between 2002 and 2006, in terms of methodology, assumptions, results and conclusions. We found a great diversity in assumptions (eg, vaccine efficacy parameters, incidence rates for both invasive and non-invasive disease) mainly due to local variation in data and opinions. Accordingly, the results varied greatly, from total net savings to over euro 100,000 per discounted QALY gained. The cost of the vaccination program (determined by price per dose and schedule (4 or 3 doses, or fewer)), and likely herd immunity impacts are highly influential though rarely explored in these published studies. If the net long-term impact (determined by a mixture of effects related to herd immunity, serotype replacement, antibiotic resistance and cross reactivity) remains beneficial and if a 3-dose schedule confers near-equivalent protection to a 4-dose schedule, the cost-effectiveness of PCV7 vaccination programs can be viewed as attractive in developed countries. Link for e-copy: http://tiny.cc/aalwe Format of e-copy: VDIC IP recognition Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1767 [article]Cost-effectiveness analysis of rotavirus vaccination of Belgian infants / J Bilcke / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2007)
![]()
Cost-effectiveness analysis of rotavirus vaccination of Belgian infants [printed text] / J Bilcke, Author ; Philippe Beutels, Author ; F De Smet, Author ; Germaine Hanquet, Author ; M. Van Ranst, Author ; Pierre Van Damme, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2007 . - vi, 143 p, 3 ann. : ill. ; 30 cm.. - (KCE Reports. Health Technology Assessment (HTA); 54C) .
0
Study nr 2007-09
Languages : English (eng)
Descriptors: Indexation
2007-09 ; Cost-effectiveness analysis ; R54 ; Rotavirus Vaccines
Classification
WC 501 RNA virus infections (General or not elsewhere classified)Link for e-copy: https://doi.org/10.57598/R54C Format of e-copy: .PDF (2,2 MB) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1641 Copies
Barcode Call number Media type Location Section Status No copy Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
![]()
Cost-effectiveness of 10- and 13-valent pneumococcal conjugate vaccines in childhood [printed text] / Philippe Beutels, Author ; Adriaan Blommaert, Author ; Germaine Hanquet, Author ; J Bilcke, Author ; Nancy Thiry, Author ; Martine Sabbe, Author ; J. Verhaegen, Author ; F De Smet, Author ; Michael Callens, Author ; Pierre Van Damme, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2011 . - VIII, 101 p. : ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 155C) .
ISSN : D/2011/10.273/21 : 0,00
Study 2009-52 (HTA): Incremental cost-effectiveness of the 7, 10 and 13-valent pneumococcal conjugate vaccines
Languages : English (eng)
Descriptors: Classification
WC 217 Pneumococcal infections
Indexation
2009-52 ; Cost-Benefit Analysis ; Infant ; Pneumococcal Infections ; Pneumococcal Vaccines ; R155 ; Vaccines ConjugateContents note: LIST OF TABLES 3-- LIST OF FIGURES 5-- GLOSSARY 6-- 1 BACKGROUND 7-- 1.1 THE SEVEN-VALENT CONJUGATE PNEUMOCOCCAL VACCINE 7-- 1.2 TWO NEW CONJUGATE PNEUMOCOCCAL VACCINES 8-- 2 OBJECTIVES AND RESEARCH QUESTIONS 9-- 3 LITERATURE SEARCHES AND METHODS 10-- 4 IMMUNOGENICITY, EFFICACY AND EFFECTIVENESS OF CURRENT-- PNEUMOCOCCAL CONJUGATE VACCINES 13-- 4.1 SEVEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV7) 13-- 4.1.1 Clinical trials efficacy of PCV7 13-- 4.1.2 Post-licensure studies effectiveness of PCV7 14-- 4.1.3 Pathogenicity of serotypes 21-- 4.2 TEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV10) 22-- 4.2.1 Clinical trials immunogenicity of PCV10 22-- 4.2.2 Clinical trials efficacy of PCV10 24-- 4.3 THIRTEEN VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) 25-- 4.3.1 Clinical trials immunogenicity of PCV13 25-- 5 DISEASE BURDEN IN BELGIUM 27-- 5.1 INVASIVE PNEUMOCOCCAL DISEASE (IPD) 28-- 5.2 ACUTE OTITIS MEDIA (AOM) AND COMMUNITY ACQUIRED PNEUMONIAE (CAP) 35-- 5.3 HOSPITALISATIONS 36-- 5.3.1 Meningitis hospitalisations 36-- 5.3.2 Bacteremia and septicaemia hospitalisations 38-- 5.3.3 Pneumonia hospitalisations 39-- 5.4 DEATHS 39-- 5.4.1 Invasive pneumococcal diseases (IPD) deaths 39-- 5.4.2 (Pneumococcal) pneumonia deaths 40-- 5.4.3 Pneumococcal meningitis deaths 40-- 5.4.4 Pneumococcal septicaemia deaths 41-- 6 ECONOMIC EVALUATIONS OF PCV10 AND PCV13 42-- 6.1 MODELS STRUCTURE 42-- 6.2 MAIN ASSUMPTIONS AND RESULTS 43-- 7 MATHEMATICAL MODELS OF PNEUMOCOCCAL TRANSMISSION 46-- 8 COST-UTILITY ANALYSIS OF PCV10 AND PCV13 IN BELGIUM 48-- 8.1 STUDY DESIGN 48-- 8.1.1 General 48-- 8.1.2 Vaccination options 48-- 8.1.3 Mathematical model structure 49-- 8.2 MODEL INPUT DATA 50-- 8.2.1 Epidemiological parameters and transition probabilities 50-- 8.2.2 Vaccine efficacy estimates 52-- 8.2.3 Direct costs 61-- 8.2.4 Health-Related Quality of Life 63-- 8.3 RESULTS 64-- 8.3.1 Cost-effectiveness acceptability curves 64-- 8.3.2 Incremental costs, outcomes and cost-effectiveness ratios 68-- 8.3.3 Further scenario analyses 77-- 8.3.4 Influence of vaccine price and of inclusion or exclusion of AOM 77-- 8.3.5 Influence of serotype replacement and herd immunity assumptions 79-- 8.3.6 Joint influence of vaccine price, expected serotype replacement and of the additional-- effectiveness of PCV10 versus PCV13 against otitis media 79-- 8.3.7 Budget impact analysis 82-- 9 CONCLUSION 83-- 10 APPENDICES: ADDITIONAL COST-EFFECTIVENESS ACCEPTABILITY-- CURVES 86-- 11 REFERENCES 88 Link for e-copy: https://doi.org/10.57598/R155C Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2572 Copies
Barcode Call number Media type Location Section Status No copy Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium / Yvres Horsmans / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2010)
![]()
Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium : Part 1: Literature review and results of a national study [printed text] / Yvres Horsmans, Author ; Nancy Thiry, Author ; Maïté le Polain, Author ; Michael Adler, Author ; Isabelle Colle, Author ; Jean Delwaide, Author ; P. Michielsen, Author ; Hans Orlent, Author ; Pierre Van Damme, Author ; Frank Hulstaert, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2010 . - VI, 111 p. : ill. ; A4. - (KCE Reports. Health Technology Assessment (HTA); 127 C) .
ISSN : D/2010/10.273/24 : 0 .
Study n : 2008-11
Languages : English (eng)
Descriptors: Indexation
2008-11 ; Antiviral Agents ; Cost-Benefit Analysis ; Hepatitis B virus ; Hepatitis B, Chronic ; Interferon-alpha ; R127
Classification
WC 536 Human viral hepatitisContents note: 1 AIMS AND METHODS 5 -- 1.1 AIMS 5 -- 1.2 METHODS 5 -- 1.3 OVERVIEW OF THE REPORT, PART 1 AND PART 2 5 -- 2 NATURAL HISTORY AND EPIDEMIOLOGY 6 -- 2.1 HEPATITIS B: TRANSITION AND NATURAL EVOLUTION 6 -- 2.1.1 Introduction 6 -- 2.1.2 Natural history of infections with the HBV 6 -- 2.1.3 Methods 8 -- 2.1.4 Results 9 -- 2.2 HBV IN BELGIUM AND SURROUNDING COUNTRIES 12 -- 2.2.1 Introduction and search strategy 12 -- 2.2.2 Epidemiology for Belgium, France, Germany and The Netherlands 12 -- 2.2.3 General Conclusion 16 -- 3 TREATMENT 17 -- 3.1 INDICATIONS FOR TREATMENT 17 -- 3.1.1 Treatment goals 17 -- 3.1.2 Definition of response 17 -- 3.1.3 Treatment options 18 -- 3.1.4 Interferon and pegylated interferon 18 -- 3.1.5 Nucleos(t)ide analogues in HBeAg-positive patients 20 -- 3.1.6 Nucleos(t)ide analogues in HBeAg-negative patients 24 -- 3.1.7 Nucleos(t)ide analogues in patients with cirrhosis or advanced fibrosis 25 -- 3.2 RECOMMENDATIONS FOR THE TREATMENT 28 -- 3.2.1 The BASL 2007 recommendations 28 -- 3.2.2 The EASL 2009 recommendations 28 -- 3.2.3 Treatment strategies 29 -- 3.2.4 Management of antiviral resistance to current NA therapy 31 -- 4 SITUATION IN BELGIUM 38 -- 4.1 HISTORY OF REIMBURSEMENT OF ANTIVIRAL DRUGS 38 -- 4.2 THE PROSPECTIVE STUDY 39 -- 4.2.1 Rationale 39 -- 4.2.2 Objectives 40 -- 4.2.3 Ethics and privacy protection 40 -- 4.2.4 Study design and schedule 41 -- 4.3 RESULTS OF THE STUDY 43 -- 4.3.1 Patient characteristics 43 -- 4.3.2 Estimation of the number of patients by disease stage, visiting a medical specialist for chronic HBV infection in Belgium. 46 -- 4.3.3 Conclusion for situation in Belgium 50 -- 4.3.4 Quality of life results 50 -- 4.3.5 Conclusion for quality of life assessment 52 -- 5 REVIEW OF THE COST-EFFECTIVENESS LITERATURE 53 -- 5.1 METHODS 53 -- 5.1.1 Literature search strategy 53 -- 5.1.2 Selection criteria 53 -- 5.1.3 Selection process 54 -- 5.2 OVERVIEW OF THE ECONOMIC EVALUATIONS - TRANSVERSAL 56 -- 5.2.1 Analytical technique 56 -- 5.2.2 Perspective 56 -- 5.2.3 Time horizon and discount rate 56 -- 5.2.4 Population 57 -- 5.2.5 Interventions 57 -- 5.2.6 Outcomes 58 -- 5.2.7 Effectiveness / modelling 61 -- 5.2.8 Costs 64 -- 5.2.9 Results 65 -- 5.3 OVERVIEW OF THE ECONOMIC EVALUATIONS - INDIVIDUAL 67 -- 5.4 GENERAL DISCUSSION AND CONCLUSIONS 70 -- 6 APPENDIXES 72 -- 7 REFERENCES 98 Link for e-copy: https://doi.org/10.57598/R127C Format of e-copy: PDF (934,96 Kb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=1909 Copies
Barcode Call number Media type Location Section Status No copy Economic evaluations of pneumococcal vaccination strategies in adults / Nancy Thiry in Acta Clinica Belgica, 60(2005)6 ([11/02/2005])
![]()
PermalinkEconomic evaluations of varicella vaccination programmes / Nancy Thiry in Pharmacoeconomics, 21(2003)1 ([01/01/2003])
![]()
PermalinkEffecten en kosten van de vaccinatie van Belgische kinderen met geconjugeerd pneumococcenvaccin / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2006)
![]()
PermalinkEffects and costs of pneumococcal conjugate vaccination of Belgian children / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2006)
![]()
PermalinkEffets et coûts de la vaccination des enfants belges au moyen du vaccin conjugué antipneumococcique / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2006)
![]()
PermalinkEvaluatie van universele en doelgroep hepatitis A vaccinatie opties in België / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
![]()
PermalinkÉvaluation de programmes de vaccination généraux et ciblés contre lhépatite A en Belgique / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2008)
![]()
PermalinkImpact of rotavirus vaccination on laboratory confirmed cases in Belgium / Germaine Hanquet in Vaccine, 29(2011)29-30 ([06/24/2011])
![]()
PermalinkKosten-effectiviteitsanalyse van rotavirus vaccinatie van zuigelingen in België / J Bilcke / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2007)
![]()
PermalinkKosteneffectiviteit van 10- en 13-valent geconjugeerde pneumokokkenvaccins bij kinderen / Philippe Beutels / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2011)
![]()
Permalink
